RU2018141714A - Слитый белок, содержащий вариант CCL3, и его применение - Google Patents
Слитый белок, содержащий вариант CCL3, и его применение Download PDFInfo
- Publication number
- RU2018141714A RU2018141714A RU2018141714A RU2018141714A RU2018141714A RU 2018141714 A RU2018141714 A RU 2018141714A RU 2018141714 A RU2018141714 A RU 2018141714A RU 2018141714 A RU2018141714 A RU 2018141714A RU 2018141714 A RU2018141714 A RU 2018141714A
- Authority
- RU
- Russia
- Prior art keywords
- fusion protein
- type
- variant
- wild
- ccl3
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims 14
- 102000037865 fusion proteins Human genes 0.000 title claims 14
- 235000001014 amino acid Nutrition 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 8
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (22)
1. Слитый белок, включающий вариант лиганда-3 типа CC (CCL3), содержащий следующие мутации, и Fc-область иммуноглобулина, причем мутации означают (1) делецию одной или двух аминокислот из N-конца CCL3 дикого типа; и (2) замену аспарагиновой кислоты в положении аминокислоты 27 с N-конца CCL3 дикого типа на аланин.
2. Слитый белок по п. 1, при этом вариант CCL3 включает вариант CCL3α, у которого удалена одна аминокислота из N-конца CCL3α дикого типа, а аспарагиновая кислота в положении аминокислоты 27 с N-конца CCL3α дикого типа заменена на аланин.
3. Слитый белок по п. 1, при этом вариант CCL3 включает вариант CCL3β, у которого удалены две аминокислоты из N-конца CCL3β дикого типа, а аспарагиновая кислота в положении аминокислоты 27 с N-конца CCL3β дикого типа заменена на аланин.
4. Слитый белок по п. 1, при этом вариант CCL3 включает последовательность SEQ ID NO: 2 или SEQ ID NO: 4.
5. Слитый белок по п. 1, при этом вариант CCL3 соединяется с Fc-областью иммуноглобулина через линкер, представленный ниже формулой 1:
(RNT)nGRGG(EEKKK)m,
где n и m равны от 1 до 5, соответственно.
6. Слитый белок по п. 5, при этом линкер включает последовательность, выбранную из SEQ ID NOs: 5-13.
7. Слитый белок по п. 1, при этом Fc-область иммуноглобулина представляет собой гибридный Fc, включающий по меньшей мере одну или несколько Fc-областей, выбранных из группы, состоящей из IgG1, IgG2, IgG3, IgG4 и IgD, их фрагментов либо их комбинаций.
8. Слитый белок по п. 7, при этом гибридный Fc включает IgG4 или его фрагмент и IgD либо его фрагмент.
9. Слитый белок по п. 1, при этом Fc-область иммуноглобулина включает последовательность SEQ ID NO: 14.
10. Нуклеиновая кислота, кодирующая слитый белок по любому из пп. 1-9.
11. Вектор, содержащий нуклеиновую кислоту по п. 10.
12. Клетка, трансформированная вектором по п. 11.
13. Способ получения слитого белка по любому из пп. 1-9, включающий:
(а) культивирование клеток по п. 12; и
(b) сбор слитого белка из прокультивированных клеток.
14. Фармацевтическая композиция, включающая слитый белок по любому из пп. 1-9.
15. Фармацевтическая композиция по п. 14, при этом композиция предназначена для лечения или профилактики рака.
16. Фармацевтическая композиция по п. 15, при этом композиция предназначена для сочетания с или при использовании лучевой терапии.
17. Вариант CCL3β (лиганда 3β типа CC), включающий следующие мутации, причем мутации означают (1) делецию одной или двух аминокислот из N-конца CCL3β дикого типа; и (2) замену аспарагиновой кислоты в положении аминокислоты 27 с N-конца CCL3β дикого типа на аланин.
18. Вариант CCL3β по п. 17, включающий последовательность SEQ ID NO: 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0053018 | 2016-04-29 | ||
| KR1020160053018A KR102682118B1 (ko) | 2016-04-29 | 2016-04-29 | Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도 |
| PCT/KR2017/004199 WO2017188653A1 (en) | 2016-04-29 | 2017-04-19 | Fusion protein comprising ccl3 variant and use thereof cross-reference to related applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018141714A true RU2018141714A (ru) | 2020-05-27 |
| RU2018141714A3 RU2018141714A3 (ru) | 2020-05-27 |
| RU2727715C2 RU2727715C2 (ru) | 2020-07-23 |
Family
ID=60160838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018141714A RU2727715C2 (ru) | 2016-04-29 | 2017-04-19 | Слитый белок, содержащий вариант CCL3, и его применение |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11046742B2 (ru) |
| EP (1) | EP3448880A4 (ru) |
| JP (1) | JP6820123B2 (ru) |
| KR (1) | KR102682118B1 (ru) |
| CN (1) | CN109328194B (ru) |
| AU (1) | AU2017256464B2 (ru) |
| BR (1) | BR112018072045A8 (ru) |
| CA (1) | CA3021680C (ru) |
| MX (1) | MX2018013177A (ru) |
| NZ (1) | NZ748614A (ru) |
| RU (1) | RU2727715C2 (ru) |
| WO (1) | WO2017188653A1 (ru) |
| ZA (1) | ZA201807140B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114007636A (zh) * | 2019-08-07 | 2022-02-01 | 平田机工株式会社 | 药物组合物 |
| MX2022006426A (es) * | 2019-11-27 | 2022-06-22 | Gi Innovation Inc | Composicion farmaceutica para el tratamiento de cancer, que comprende inhibidor de punto de control inmunologico y proteina de fusion que incluye proteina il-2 y proteina cd80. |
| WO2024239143A1 (zh) * | 2023-05-19 | 2024-11-28 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| CN117466986A (zh) * | 2023-10-30 | 2024-01-30 | 中南大学 | 一种趋化因子ccl3的制备方法及其在制备肿瘤免疫治疗药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993013206A1 (en) * | 1991-12-23 | 1993-07-08 | British Bio-Technology Limited | Stem cell inhibiting proteins |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| WO2003062370A2 (en) * | 2001-07-19 | 2003-07-31 | Perlan Therapeutics, Inc. | Multimeric proteins and methods of making and using same |
| WO2003051921A1 (en) * | 2001-12-17 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Chemokine mutants acting as chemokine antagonists |
| CA2507008A1 (en) * | 2002-12-23 | 2004-07-29 | Applied Research Systems Ars Holding N.V. | Use of cc-chemokine mutants against liver diseases |
| EP1507147A1 (en) | 2003-08-12 | 2005-02-16 | Erasmus University Medical Center Rotterdam | Method for detecting low levels of a fusion protein |
| US20070161550A1 (en) * | 2003-12-30 | 2007-07-12 | Wyeth | Antiviral compositions which inhibit paramyxovirus infection |
| US7638319B2 (en) * | 2005-03-07 | 2009-12-29 | New York University | Method for determining co-receptor selectivity of Human Immunodeficiency Virus-1 |
| CA2618951A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| WO2007113285A2 (en) * | 2006-03-31 | 2007-10-11 | Biotherapix Molecular Medicines S.L.U. | Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors |
| US8445442B2 (en) | 2007-04-26 | 2013-05-21 | University Of Vermont And State Agricultural College | CCL18 and CCL3 methods and compositions for detecting and treating cancer |
| JP5577243B2 (ja) * | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
| AU2011268934B2 (en) * | 2010-06-25 | 2015-09-10 | Nykode Therapeutics ASA | Homodimeric protein constructs |
| WO2012023631A1 (ja) * | 2010-08-19 | 2012-02-23 | 株式会社Eci | ヒートショックプロテイン（ｈｓｐ）とｅｃｉ３０１ポリペプチドを含む癌細胞の増殖を抑制するための医薬組成物ならびにそれを用いた癌の治療方法 |
| EP2714065A4 (en) * | 2011-06-01 | 2015-04-08 | Jyant Technologies | CHEMOKINE-IMMUNOGLOBULIN FUSION POLYPEPTIDES, COMPOSITIONS, PROCESS FOR THEIR MANUFACTURE AND USE |
| EP2543680A1 (en) * | 2011-07-07 | 2013-01-09 | Centre National de la Recherche Scientifique | Multispecific mutated antibody Fab fragments |
| US20160115216A1 (en) | 2013-06-07 | 2016-04-28 | Novo Nordisk A/S | Method for Making Mature Insulin Polypeptides |
-
2016
- 2016-04-29 KR KR1020160053018A patent/KR102682118B1/ko active Active
-
2017
- 2017-04-19 NZ NZ748614A patent/NZ748614A/en unknown
- 2017-04-19 RU RU2018141714A patent/RU2727715C2/ru active
- 2017-04-19 MX MX2018013177A patent/MX2018013177A/es unknown
- 2017-04-19 BR BR112018072045A patent/BR112018072045A8/pt unknown
- 2017-04-19 WO PCT/KR2017/004199 patent/WO2017188653A1/en not_active Ceased
- 2017-04-19 CA CA3021680A patent/CA3021680C/en active Active
- 2017-04-19 AU AU2017256464A patent/AU2017256464B2/en active Active
- 2017-04-19 US US16/097,572 patent/US11046742B2/en active Active
- 2017-04-19 JP JP2018555968A patent/JP6820123B2/ja active Active
- 2017-04-19 EP EP17789838.4A patent/EP3448880A4/en not_active Withdrawn
- 2017-04-19 CN CN201780034564.9A patent/CN109328194B/zh active Active
-
2018
- 2018-10-25 ZA ZA2018/07140A patent/ZA201807140B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516363A (ja) | 2019-06-20 |
| EP3448880A4 (en) | 2019-12-04 |
| JP6820123B2 (ja) | 2021-01-27 |
| MX2018013177A (es) | 2019-05-27 |
| KR102682118B1 (ko) | 2024-07-08 |
| RU2727715C2 (ru) | 2020-07-23 |
| BR112018072045A8 (pt) | 2023-01-17 |
| AU2017256464A1 (en) | 2018-12-13 |
| CA3021680A1 (en) | 2017-11-02 |
| US20190153055A1 (en) | 2019-05-23 |
| EP3448880A1 (en) | 2019-03-06 |
| US11046742B2 (en) | 2021-06-29 |
| CN109328194B (zh) | 2022-04-19 |
| BR112018072045A2 (pt) | 2019-06-04 |
| AU2017256464B2 (en) | 2019-08-15 |
| CA3021680C (en) | 2022-03-15 |
| ZA201807140B (en) | 2019-07-31 |
| WO2017188653A1 (en) | 2017-11-02 |
| KR20170123849A (ko) | 2017-11-09 |
| CN109328194A (zh) | 2019-02-12 |
| RU2018141714A3 (ru) | 2020-05-27 |
| NZ748614A (en) | 2020-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12447208B2 (en) | Anti-CTLA4 monoclonal antibody or its antigen binding fragments, pharmaceutical compositions and uses | |
| ES2914177T3 (es) | Anticuerpos anti-OX40 humanizados y usos de los mismos | |
| RU2013140472A (ru) | Слитый белок антиангиогенного индуцирующего фактора и его применение | |
| RU2015140624A (ru) | Т-клетки, перенацеленные в отношении cd123-специфичного химерного антигенного рецептора, и способы их применения | |
| RU2013129694A (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| RU2018119141A (ru) | Слитые с fgf21 белки длительного действия и содержащая их фармацевтическая композиция | |
| KR20220024837A (ko) | Tigit에 대한 항체 | |
| JP2015518479A5 (ru) | ||
| RU2022102624A (ru) | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков | |
| CN113227134A (zh) | 抗体的Fc区变体 | |
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| RU2018141714A (ru) | Слитый белок, содержащий вариант CCL3, и его применение | |
| RU2017103675A (ru) | Способ размещения в цитоплазме антител в виде полного иммуноглобулина путем проникновения антител через клеточную мембрану и его применение | |
| ES2710976T3 (es) | Anticuerpos anti-CD52 | |
| HRP20220884T1 (hr) | Proteini specifični za baff i b7rp1 i njihova uporaba | |
| CA3195315A1 (en) | Compositions and methods for selective depletion of target molecules | |
| KR20210107747A (ko) | 항체 융합 단백질, 이의 제조 방법 및 이의 적용 | |
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| CA3197642A1 (en) | Polypeptides targeting sars-cov-2 and related compositions and methods | |
| EP2758072A1 (en) | Vaccibodies targeted to cross-presenting dendritic cells | |
| KR20150134319A (ko) | 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편 | |
| JP2014124186A (ja) | 多価抗体フラグメントおよびその三量体化複合体 | |
| AU2021374036A1 (en) | Polypeptide constructs selectively binding to cldn6 and cd3 | |
| CN109879966B (zh) | 基于鼠源cd19抗体的人源化设计及表达验证 |